SOLT.F Stock Overview Develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Nxera Pharma Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nxera Pharma Historical stock prices Current Share Price JP¥6.52 52 Week High JP¥13.43 52 Week Low JP¥6.16 Beta 0.61 1 Month Change 0% 3 Month Change n/a 1 Year Change -25.23% 3 Year Change -48.94% 5 Year Change -63.88% Change since IPO -84.92%
Recent News & Updates Nxera Pharma Co., Ltd., Annual General Meeting, Mar 26, 2025
Nxera Pharma Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 03
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea Dec 05
Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma Oct 01
Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024 Sep 12
Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024 Jun 15 See more updates Nxera Pharma Co., Ltd., Annual General Meeting, Mar 26, 2025
Nxera Pharma Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 03
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea Dec 05
Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma Oct 01
Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024 Sep 12
Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024 Jun 15
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 Apr 16
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC Apr 03
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease Mar 21
Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024 Mar 08
Sosei Group Corporation, Annual General Meeting, Mar 27, 2024 Feb 13
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer Jan 05
Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea Dec 07
Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024 Nov 30
Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant Nov 01
Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023 Aug 27
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732 Aug 10
Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion. Jul 22
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia Jul 04
Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023 Jun 26
Sosei Group Corporation, Annual General Meeting, Mar 23, 2023 Feb 14
Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023 Dec 06
Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022 Sep 10
Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences Aug 06
Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials Jul 22
Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022 Jun 03
Sosei Group Corporation, Annual General Meeting, Mar 24, 2022 Feb 01
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 Dec 09
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven Jun 24
Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer May 19
Sosei Group Corporation to Report Q1, 2021 Results on May 12, 2021 Mar 20
Sosei Group Corporation, Annual General Meeting, Mar 24, 2021 Feb 12
Sosei Heptares to Explore Structure-Based Drug Discovery (SBDD) Approaches to Ion Channels Through Strategic Technology Collaboration with Metrion Biosciences Feb 01
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-Driven Drug Discovery Against Challenging GPCR Target Jan 12
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs Jan 05 Sosei Group Corporation's Brand Sosei Heptares and Captor Therapeutics SA Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Sosei Group Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021 Dec 05
Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio Dec 02
Sosei Group Corporation Announces Progress Update for Its R&D Program Focused on the Design and Development of Novel Drugs Targeting the SARS-CoV-2 Coronavirus and to Treat COVID-19 Nov 21
Sosei Heptares Announces a Second Novel Drug Candidate from its Multi-Target Drug Discovery Collaboration with Pfizer Starts Clinical Trials Oct 05
Sosei Group Corporation to Report Q3, 2020 Results on Nov 11, 2020 Sep 11
Sosei Group Corporation has completed a Follow-on Equity Offering in the amount of ¥5.265733 billion. Jul 18
Sosei Group Corporation to Report Q2, 2020 Results on Aug 13, 2020 Jul 05 Shareholder Returns SOLT.F US Pharmaceuticals US Market 7D 0% 0.6% -0.4% 1Y -25.2% -1.1% 20.8%
See full shareholder returns
Return vs Market: SOLT.F underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is SOLT.F's price volatile compared to industry and market? SOLT.F volatility SOLT.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 9.8% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SOLT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SOLT.F's volatility change over the past year.
About the Company Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology.
Show more Nxera Pharma Co., Ltd. Fundamentals Summary How do Nxera Pharma's earnings and revenue compare to its market cap? SOLT.F fundamental statistics Market cap US$516.46m Earnings (TTM ) -US$32.21m Revenue (TTM ) US$191.95m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SOLT.F income statement (TTM ) Revenue JP¥28.84b Cost of Revenue JP¥7.62b Gross Profit JP¥21.22b Other Expenses JP¥26.06b Earnings -JP¥4.84b
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -53.81 Gross Margin 73.59% Net Profit Margin -16.78% Debt/Equity Ratio 92.7%
How did SOLT.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/20 07:43 End of Day Share Price 2025/01/06 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Nxera Pharma Co., Ltd. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Koichi Mamegano BofA Global Research Hidemaru Yamaguchi Citigroup Inc null null Credit Suisse
Show 15 more analysts 
